Wang R Z, Zhong W Q, Guan S R
Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing.
Zhonghua Zhong Liu Za Zhi. 1994 Mar;16(2):98-101.
For the purpose of enhancing the therapeutic index and reducing the toxic effect of chemotherapeutic drugs, Dau-HA-Ms was prepared, mostly as monodispersed microspheres with a mean diameter of 52 +/- 16 microns, ranging from 29 to 194 microns, being suitable for the use of transarterial embolization (TAE) therapy. Dau released effectively in physiological saline solution from microspheres without burst release. The spectrophotometric characteristics and cytotoxic effect in vitro of the released Dau remained unchanged, retaining the original physicochemical and biological properties. It was demonstrated that 30% of mice bearing S-180 sarcoma ascites treated with intraperitoneal injection of Dau-HA-MS survived longer than 6 months, while all tumor bearing control mice and Dau treated tumor bearing mice died within 21 and 14 days, respectively. The results show that Dau-HA-MS is therapeutically more effective and less toxic than Dau, Dau-HA-MS can possibly be used in TAE therapy for human liver cancer.
为提高化疗药物的治疗指数并降低其毒副作用，制备了Dau-HA-Ms，其大多为单分散微球，平均直径为52±16微米，范围为29至194微米，适用于经动脉栓塞（TAE）治疗。Dau在生理盐水中能从微球中有效释放，无突发释放现象。释放出的Dau的分光光度特性和体外细胞毒性作用保持不变，保留了其原始的物理化学和生物学特性。结果表明，腹腔注射Dau-HA-MS治疗的荷S-180肉瘤腹水小鼠中有30%存活超过6个月，而所有荷瘤对照小鼠和经Dau治疗的荷瘤小鼠分别在21天和14天内死亡。结果表明，Dau-HA-MS在治疗上比Dau更有效且毒性更小，Dau-HA-MS可能可用于人类肝癌的TAE治疗。
